EUDA vs VERU Comparison

EUDA Health Holdings Ltd is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. It offers inventive, accessible, and science-based health solutions to support the shift in regional healthcare from reactive medical treatment to proactive, longevity-focused care. The group also runs a Singapore-based property management business. It operates in two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include management and security services for properties such as condominiums, residential apartments, business office buildings, and shopping malls.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.